AAV-shrna
AAV-shrna has been studied in 2 papers since 2021: none in people yet, 2 in animals; 1 in the past year. The research so far is in animals. The newest paper, May 18, 2026: “Inhibition of TWEAK/Fn14 Ameliorates Sarcopenic Obesity by Restoring Mitochondrial Biogenesis via the AMPK/SIRT1/PGC-1α Axis”.
2 papers study it4 findingsUpdated
None of its findings points the other way.
- 1 lab in 1 country
- Animals2
What did studies of AAV-shrna find?
4Studies of AAV-shrna measured 4 outcomes; the most studied are AMPK/SIRT1/PGC-1α signaling (1 study), P38 MAPK phosphorylation (1) and adiposity (1).
AMPK/SIRT1/PGC-1α signaling
upin mice1
1 study
AMPK/SIRT1/PGC-1α signaling
upin mice1
AAV-shrna activates AMPK/SIRT1/PGC-1α signaling in mice.
“the reactivation of the AMPK/SIRT1/PGC-1α signaling axis, a key driver of mitochondrial biogenesis”
AnimalsAAV-shRNA
Diabetes, metabolic syndrome and obesity : targets and therapy
P38 MAPK phosphorylation
downin mice1
1 study
P38 MAPK phosphorylation
downin mice1
AAV-shrna decreases P38 MAPK phosphorylation in mice.
“the downregulation of p38 MAPK phosphorylation and the reactivation of the AMPK/SIRT1/PGC-1α signaling axis, a key driver of mitochondrial biogenesis”
AnimalsAAV-shRNA
Diabetes, metabolic syndrome and obesity : targets and therapy
Adiposity
downin mice1
1 study
Adiposity
downin mice1
AAV-shrna decreases adiposity in mice (high-fat diet-fed aged mice with sarcopenic obesity).
“TWEAK inhibition effectively reverses the SO phenotype, characterized by improved grip strength, reduced adiposity, and lowered systemic inflammation and lipid levels.”
Animalshigh-fat diet-fed aged mice with sarcopenic obesityAAV-shRNA12 weeksmales
Diabetes, metabolic syndrome and obesity : targets and therapy
Grip strength
upin mice1
1 study
Grip strength
upin mice1
AAV-shrna improves grip strength in mice (high-fat diet-fed aged mice with sarcopenic obesity).
“TWEAK inhibition effectively reverses the SO phenotype, characterized by improved grip strength, reduced adiposity, and lowered systemic inflammation and lipid levels.”
Animalshigh-fat diet-fed aged mice with sarcopenic obesityAAV-shRNAskeletal muscle12 weeksmales
Diabetes, metabolic syndrome and obesity : targets and therapy